Business
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program.Defence has been collaborating with CNL on the...
About this update from Defence Therapeutics Inc Class A
[{"type":"text","content":"Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program.","length":475,"tagName":"p"},{"type":"text","content":"Defence has been collaborating with CNL on the development of an Accum®-enhanced radio-immunoconjugate program. This program is now approaching a key inflection point, with critical results being generated by both lab teams on this program that are intended to support candidate selection and enable preparation for first-in-human clinical studies.","length":348,"tagName":"p"},{"type":"text","content":"Based on the exciting traction on the lead program, Defence and CNL are expanding their collaboration to initiate multiple other radioisotopes programs with Defence's proprietary Accum®, positioning the Company to rapidly expand its radiopharmaceutical portfolio as new data and strategic priorities emerge.","length":311,"tagName":"p"},{"type":"text","content":"Radiopharmaceutical therapies require precise intracellular and nuclear localization to maximize efficacy, as radioactive payloads must reach the vicinity of the cell nucleus to induce lethal DNA damage. Defence's proprietary Accum® platform enables active intracellular and nuclear transport, unlocking the full therapeutic potential of targeted radiotherapies while increasing potency and reducing toxicity.","length":413,"tagName":"p"},{"type":"text","content":""This collaboration with CNL has become a cornerstone of our radiopharmaceutical strategy," said Sébastien Plouffe, CEO of Defence Therapeutics. "Radiopharmaceuticals now represent one of our top development priorities alongside our ADC program. By deepening our work with CNL and leveraging their world-class nuclear science expertise, we are building a strong, proprietary pipeline in this space and accelerating our path toward the clinic."","length":463,"tagName":"p"},{"type":"text","content":""We have worked in close collaboration with Defence on their flagship progr...